Concepedia

Association between the treatment length and cumulative dose of pegylated interferon alpha‐2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: Project of the Kyushu University Liver Disease Study Group

Norihiro Furusyo, Eiji Kajiwara, Kazuhiro Takahashi, Hideyuki Nomura, Yuichi Tanabe, Akihide Masumoto, Toshihiro Maruyama, Makoto Nakamuta, Munechika Enjoji, Koichi Azuma,

Journal of Gastroenterology and Hepatology · 2008 · 47 citations · 24 references

DOI

Abstract

In peg-IFN alpha-2b plus RBV treatment for chronic hepatitis C, it is important to complete the target length of treatment and to continue the target dosage to achieve SVR, especially for genotype 1 patients.

References

24

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Michael P. Manns, John G. McHutchison, Stuart C. Gordon et al. · The Lancet · 2001 · 6K citations

, , +7

Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C

John G. McHutchison, Stuart C. Gordon, Eugene R. Schiff et al. · New England Journal of Medicine · 1998 · 3.5K citations · Full text

Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C

Stephanos J. Hadziyannis · Annals of Internal Medicine · 2004 · 2.8K citations

Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus

Thierry Poynard, Patrick Marcellin, Samuel S. Lee et al. · The Lancet · 1998 · 2.3K citations

, , +9

Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region

Peter Simmonds, Bruce Irvine, P.L. Yap et al. · Journal of General Virology · 1993 · 1.4K citations · Full text